Triple-negative breast cancer molecular subtyping and treatment progress

By Li Yin, Jiang-jie Duan, X. Bian, Shi-cang Yu. Breast Cancer Research, 2020

2,026 citations recorded by the source corpus.

Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking. Therefore, development of new TNBC treatment strategies has become an urgent clinical need. By summarizing existing treatment regimens, therapeutic drugs, and their efficacy for different TNBC subtypes and reviewing some new preclinical studies and targeted treatment regimens for TNBC, this paper aims to provide new ideas for TNBC treatment.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e85a0e42fca79345acb742e4ac836c60863b06a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Yongheng Chen
2. S. Leonov
3. Huajun Zhang
4. Lin Chen
5. Na Liu
6. Yun R Li
7. Yulia Merkher

In Pulmonary and Respiratory Medicine

1. Yongheng Chen
2. S. Leonov
3. Huajun Zhang
4. Lin Chen
5. Na Liu
6. Yun R Li
7. Yulia Merkher

Citations in the corpus

• Recent advances in therapeutic strategies for triple-negative breast cancer (2022, background): “ER-α36 was discovered in both ER-positive breast cancer cells and TNBC cell lines, and a subsequent study in TNBC identified a positive feedback loop of ER-α36/EGFR, indicating responsiveness to mitogenic estrogen signaling in ER-α36 expressing TNBC [71, 72].”